Market Closed -
Hong Kong S.E.
04:08:05 2024-05-31 am EDT
|
5-day change
|
1st Jan Change
|
20.35
HKD
|
-3.78%
|
|
-10.35%
|
-13.59%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
11,730
|
62,629
|
53,868
|
24,455
|
11,353
|
8,140
|
-
|
-
|
Enterprise Value (EV)
1 |
11,142
|
58,324
|
49,253
|
24,455
|
11,353
|
7,582
|
7,602
|
7,357
|
P/E ratio
|
-74.8
x
|
-86.4
x
|
19
x
|
-16
x
|
-3.65
x
|
-15.4
x
|
-312
x
|
16.9
x
|
Yield
|
-
|
-
|
0.54%
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
3,377
x
|
12.5
x
|
23.6
x
|
31.8
x
|
9.46
x
|
6.71
x
|
4.58
x
|
EV / Revenue
|
-
|
3,145
x
|
11.5
x
|
23.6
x
|
31.8
x
|
8.81
x
|
6.27
x
|
4.14
x
|
EV / EBITDA
|
-62.8
x
|
-158
x
|
24.4
x
|
-24.6
x
|
-7.01
x
|
-48.2
x
|
41
x
|
12.3
x
|
EV / FCF
|
-39.8
x
|
-78.9
x
|
58.2
x
|
-8.36
x
|
-7.48
x
|
-16.1
x
|
-130
x
|
25.6
x
|
FCF Yield
|
-2.52%
|
-1.27%
|
1.72%
|
-12%
|
-13.4%
|
-6.2%
|
-0.77%
|
3.91%
|
Price to Book
|
7.28
x
|
6.06
x
|
4.54
x
|
1.97
x
|
1
x
|
0.94
x
|
0.94
x
|
0.89
x
|
Nbr of stocks (in thousands)
|
222,650
|
247,450
|
247,450
|
246,766
|
246,766
|
247,044
|
-
|
-
|
Reference price
2 |
52.68
|
148.6
|
146.8
|
58.95
|
21.40
|
18.85
|
18.85
|
18.85
|
Announcement Date
|
3/27/20
|
2/25/21
|
2/25/22
|
2/27/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
18.54
|
4,300
|
1,035
|
357.1
|
860.3
|
1,213
|
1,779
|
EBITDA
1 |
-177.5
|
-369.1
|
2,021
|
-993.4
|
-1,621
|
-157.3
|
185.6
|
596.4
|
EBIT
1 |
-200
|
-400.9
|
1,941
|
-1,181
|
-1,936
|
-347.5
|
-7.418
|
376.8
|
Operating Margin
|
-
|
-2,161.66%
|
45.14%
|
-114.12%
|
-542.3%
|
-40.39%
|
-0.61%
|
21.19%
|
Earnings before Tax (EBT)
1 |
-156.8
|
-396.6
|
1,937
|
-1,184
|
-1,932
|
-345.4
|
-0.2572
|
227.4
|
Net income
1 |
-156.8
|
-396.6
|
1,914
|
-909.4
|
-1,447
|
-285.9
|
-5.295
|
157.2
|
Net margin
|
-
|
-2,138.9%
|
44.52%
|
-87.9%
|
-405.31%
|
-33.23%
|
-0.44%
|
8.84%
|
EPS
2 |
-0.7041
|
-1.720
|
7.740
|
-3.680
|
-5.870
|
-1.220
|
-0.0604
|
1.113
|
Free Cash Flow
1 |
-280.2
|
-739.3
|
846.9
|
-2,927
|
-1,518
|
-470
|
-58.29
|
287.9
|
FCF margin
|
-
|
-3,986.61%
|
19.7%
|
-282.87%
|
-425.22%
|
-54.63%
|
-4.81%
|
16.19%
|
FCF Conversion (EBITDA)
|
-
|
-
|
41.9%
|
-
|
-
|
-
|
-
|
48.27%
|
FCF Conversion (Net income)
|
-
|
-
|
44.24%
|
-
|
-
|
-
|
-
|
183.1%
|
Dividend per Share
2 |
-
|
-
|
0.8000
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/27/20
|
2/25/21
|
2/25/22
|
2/27/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
1,214
|
-
|
130.4
|
77.6
|
-
|
-
|
-
|
-
|
181.5
|
114.3
|
225.6
|
225.6
|
341
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
645.5
|
-
|
-
|
-
|
-507.7
|
-
|
-
|
-
|
-
|
-
|
-92.24
|
-92.24
|
-92.24
|
-
|
-
|
Operating Margin
|
53.18%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-40.88%
|
-40.88%
|
-27.05%
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-139.5
|
-701.9
|
-143.6
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
2.350
|
0.4900
|
-
|
-
|
-1.760
|
-0.5700
|
-2.840
|
-0.5800
|
-
|
-0.6900
|
-0.3714
|
-0.3714
|
-0.3553
|
-
|
-
|
Dividend per Share
2 |
0.8000
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/25/22
|
4/28/22
|
9/8/22
|
10/28/22
|
2/27/23
|
4/28/23
|
8/30/23
|
10/30/23
|
2/23/24
|
4/29/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
588
|
4,304
|
4,614
|
-
|
-
|
558
|
538
|
783
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-280
|
-739
|
847
|
-2,927
|
-1,518
|
-470
|
-58.3
|
288
|
ROE (net income / shareholders' equity)
|
-15.9%
|
-10.5%
|
27.1%
|
-12.4%
|
-24.7%
|
-5.91%
|
-0.43%
|
5.42%
|
ROA (Net income/ Total Assets)
|
-12.2%
|
-9.3%
|
25.9%
|
-
|
-13.9%
|
-4.5%
|
-0.86%
|
-4.3%
|
Assets
1 |
1,290
|
4,266
|
7,383
|
-
|
10,394
|
6,353
|
612.8
|
-3,656
|
Book Value Per Share
2 |
7.230
|
24.50
|
32.30
|
30.00
|
21.40
|
20.00
|
20.00
|
21.10
|
Cash Flow per Share
2 |
-0.8400
|
-2.030
|
8.290
|
-7.640
|
-3.680
|
-1.000
|
0.8700
|
1.840
|
Capex
1 |
110
|
270
|
1,203
|
1,075
|
610
|
162
|
223
|
254
|
Capex / Sales
|
-
|
1,455.39%
|
27.98%
|
103.91%
|
170.87%
|
18.87%
|
18.36%
|
14.3%
|
Announcement Date
|
3/27/20
|
2/25/21
|
2/25/22
|
2/27/23
|
2/23/24
|
-
|
-
|
-
|
Last Close Price
18.85
CNY Average target price
25.66
CNY Spread / Average Target +36.16% Consensus |
1st Jan change
|
Capi.
|
---|
| -13.59% | 1.14B | | -2.29% | 89.38B | | -3.95% | 37.92B | | -13.07% | 32.04B | | +63.05% | 26.03B | | -22.14% | 14.14B | | -7.96% | 12.88B | | -9.33% | 11.77B | | -46.33% | 10.85B | | +5.77% | 8.92B |
Biopharmaceuticals
|